Alimera Sciences (ALIM)
Alimera Sciences (ALIM) is a pharmaceutical company that develops and commercializes ophthalmic pharmaceuticals in the US & internationally that are focused on the back of the eye or retina. The company’s lead product is Iluvien, a 3 year intravitreal implant for the treatment of diabetic macular edema (DME), a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.
Published Reports
ALIM roadshow 3.4.19 rev
ALIM 4Q18 rev
ALIM FY18 prelim rev
ALIM 3Q18 rev
ALIM 2Q18 rev
ALIM 1Q18 rev
ALIM 4Q17 rev
ALIM USER study rev
ALIM 2Q17 rev
ALIM-Enrollment-Reduction-rev.pdf
ALIM Label Expansion and Conversion
ALIM-1Q17-rev.pdf
ALIM KOL 3.7.17 rev
ALIM 4Q16 rev
alim-3q16-jfm-edits-rev
alim-roadshow-9-21-16-rev
ALIM 2Q16 rev
ALIM 1Q16 rev
ALIM 4Q15 rev
ALIM 3Q15-1 rev
ALIM.2Q15 rev
ALIM Management Day 7.7.15
ALIM initiation
ALIM.1Q15.5.7.15 rev